Tags

Type your tag names separated by a space and hit enter

Advances in therapy with antileukotriene drugs.

Abstract

Evidence from clinical trials and experience derived from managing patients with asthma justify a broader role for leukotriene (LT) blockers in asthma management than that recommended by the National Asthma Education and Prevention Program and the NIH Heart, Lung and Blood Institute treatment guidelines. Many published clinical trials, reviews, and case reports have suggested important new applications of LT blockers (ie, montelukast, zafirlukast, pranlukast, and zileuton) in several diseases in which leukotrienes play a pathogenic role. These include paranasal sinus disease, allergic fungal sinusitis, migraine, chronic urticaria, atopic dermatitis, chronic obstructive pulmonary disease, allergic conjunctivitis, mastocytosis, bronchiolitis, idiopathic pulmonary fibrosis, interstitial cystitis, and irritable bowel syndrome. Although double-blind, randomized, placebo-controlled trials are needed to confirm the effects that these drugs may have in these diseases, the aim of this short review is to delineate the future roles that these drugs may have in the management of these conditions.

Links

  • Publisher Full Text
  • Authors+Show Affiliations

    ,

    Department of Biomedical Sciences, University G. D'Annunzio, Chieti, Italy. griccioni@hotmail.com

    , , ,

    Source

    MeSH

    Anti-Asthmatic Agents
    Asthma
    Humans
    Leukotriene Antagonists
    Leukotrienes
    Randomized Controlled Trials as Topic

    Pub Type(s)

    Journal Article
    Review

    Language

    eng

    PubMed ID

    15648777

    Citation

    Riccioni, Graziano, et al. "Advances in Therapy With Antileukotriene Drugs." Annals of Clinical and Laboratory Science, vol. 34, no. 4, 2004, pp. 379-87.
    Riccioni G, Di Ilio C, Conti P, et al. Advances in therapy with antileukotriene drugs. Ann Clin Lab Sci. 2004;34(4):379-87.
    Riccioni, G., Di Ilio, C., Conti, P., Theoharides, T. C., & D'Orazio, N. (2004). Advances in therapy with antileukotriene drugs. Annals of Clinical and Laboratory Science, 34(4), pp. 379-87.
    Riccioni G, et al. Advances in Therapy With Antileukotriene Drugs. Ann Clin Lab Sci. 2004;34(4):379-87. PubMed PMID: 15648777.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Advances in therapy with antileukotriene drugs. AU - Riccioni,Graziano, AU - Di Ilio,Carmine, AU - Conti,Pio, AU - Theoharides,Theoharis C, AU - D'Orazio,Nicolantonio, PY - 2005/1/15/pubmed PY - 2005/4/29/medline PY - 2005/1/15/entrez SP - 379 EP - 87 JF - Annals of clinical and laboratory science JO - Ann. Clin. Lab. Sci. VL - 34 IS - 4 N2 - Evidence from clinical trials and experience derived from managing patients with asthma justify a broader role for leukotriene (LT) blockers in asthma management than that recommended by the National Asthma Education and Prevention Program and the NIH Heart, Lung and Blood Institute treatment guidelines. Many published clinical trials, reviews, and case reports have suggested important new applications of LT blockers (ie, montelukast, zafirlukast, pranlukast, and zileuton) in several diseases in which leukotrienes play a pathogenic role. These include paranasal sinus disease, allergic fungal sinusitis, migraine, chronic urticaria, atopic dermatitis, chronic obstructive pulmonary disease, allergic conjunctivitis, mastocytosis, bronchiolitis, idiopathic pulmonary fibrosis, interstitial cystitis, and irritable bowel syndrome. Although double-blind, randomized, placebo-controlled trials are needed to confirm the effects that these drugs may have in these diseases, the aim of this short review is to delineate the future roles that these drugs may have in the management of these conditions. SN - 0091-7370 UR - https://www.unboundmedicine.com/medline/citation/15648777/full_citation L2 - http://www.annclinlabsci.org/cgi/pmidlookup?view=long&pmid=15648777 DB - PRIME DP - Unbound Medicine ER -